Molecular and Cellular Biology, November 2001, p. 7761-7774, Vol. 21, No. 22
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.22.7761-7774.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Departments of Internal Medicine1 and Pediatrics,3 University of Ulm, D-89081 Ulm, and Institute for Medical Microbiology and Hygiene, University of Regensburg, D-93053 Regensburg,2 Germany
Received 16 March 2001/Returned for modification 29 April 2001/Accepted 2 August 2001
| |
ABSTRACT |
|---|
|
|
|---|
Notch-1 belongs to a family of transmembrane receptor proteins that
direct the decisions as to various cell fates. After ligand binding, a
proteolytic cleavage step occurs and the intracellular part of Notch-1,
Notch-1-IC, translocates into the nucleus, where it targets the DNA
binding protein RBP-J
/CBF1. RBP-J
mediates repression through
recruitment of a histone deacetylase-containing complex. The
Notch-1-IC/RBP-J
complex overcomes repression and activates the
transcription of Notch target genes. We have identified a novel domain
in Notch-1-IC, the EP domain, which is indispensable for full
transcriptional activation. This transactivation domain is localized
adjacent to the ankyrin repeats of Notch-1-IC. In cotransfection
experiments, Notch-1-IC-mediated transcriptional activation was
inhibited by E1A12S and p53, two proteins, which interfere with the
function of the common coactivator p300. Protein-protein interaction
assays demonstrated the association of Notch-1-IC and the CH3 region of
p300. In addition, the interaction of mammalian Notch-1-IC with p300
was destabilized after deletion of the EP domain of Notch-1-IC. Based
on physical interaction with Notch-1-IC and coactivator functions of
p300, we propose a model for Notch-1-mediated gene regulation via p300.
| |
INTRODUCTION |
|---|
|
|
|---|
The Notch signaling pathway is a highly conserved signaling mechanism, which is believed to control cell fate decisions in multiple developmental programs (2). In vertebrates, Notch proteins comprise a family of four transmembrane receptors (Notch-1 to Notch-4) that contain multiple epidermal growth factor-like repeats followed by conserved cysteine-rich Notch/Lin12 repeats in their extracellular domain and six cdc10/ankyrin repeats in their intracellular domain. The Notch ligands (Jagged-1, Jagged-2, and Delta-1 to Delta-3) represent transmembrane proteins that, like Notch, contain multiple epidermal growth factor-like repeats in their extracellular domain (11). Ligand binding leads to a cleavage step near the transmembrane region of the C-terminal protein fragment, resulting in the release of the intracellular domain (Notch-IC) followed by its nuclear translocation (41, 46).
An important nuclear target of activated Notch-1 is the ubiquitous DNA
binding protein RBP-J
/CBF-1, the mammalian homologue of
Drosophila melanogaster Suppressor of Hairless [Su(H)]
(13, 15). Activated Notch interacts with RBP-J
/Su(H)
primarily through the RAM23 domain, a sequence that was identified
N-terminal to the ankyrin repeats, resulting in activation of
transcription (47). Downstream targets of Notch signaling
such as Enhancer of split [E(spl)] complex genes (4,
28) and mammalian homologues of Hairy and E(spl)
genes, HES-1 and HES-5, (18, 32) have been identified.
These basic helix-loop-helix (bHLH) proteins antagonize other bHLH
factors like MyoD that induce differentiation (25).
In the absence of Notch-1-IC, RBP-J
acts as a transcriptional
repressor (9, 36). Recent data indicate that
RBP-J
-mediated repression includes destabilization of the
transcription factor IID (TFIID)-TFIIA interaction (33)
and recruitment of histone deacetylase corepressor complexes (16,
20).
Whereas hypoacetylated histones are implicated in gene silencing,
hyperacetylated histones accumulate within transcriptionally active
genes (24). Indeed, many transcription factors associate with histone acetyltransferase activity. One of these proteins, p300,
belongs to a family of transcriptional coactivators that also includes
the closely related cyclicAMP response element binding protein, CBP.
The p300 protein associates with many classes of transcription factors
including basic leucine zipper (bZIP) proteins like Jun and Fos
(1), nuclear receptors (7), members of the
NF-
B family (37), and bHLH proteins (53).
After association with RBP-J
, Notch-IC stimulates the expression of
target genes by overcoming RBP-J
-mediated repression and activation
of transcription through the presence of an endogenous transactivation
domain (15, 27). In addition, recent studies by Kurooka et
al. demonstrated a functional interaction of Notch-1-IC with the
histone acetyltransferases P/CAF and GCN5 (26).
Here we present the identification and characterization of a novel domain within the C-terminal protein fragment of mammalian Notch-1, which we named the EP domain. Deletion of this domain did not interfere with nuclear localization but abolished Notch-1-mediated transactivation of both an artificial promoter construct and the murine HES-1 promoter. Protein-protein interaction assays demonstrated that the intracellular part of Notch-1 (Notch-1-IC) is targeted by the common coactivator p300. Coimmunoprecipitation assays indicate that deletion of the EP domain within Notch-1-IC destabilizes the interaction with p300 in vivo. Furthermore, in cotransfection experiments, mNotch-1-IC-mediated transactivation was inhibited by E1A12S and p53, two proteins that interfere with p300 function. Our results suggest that recruitment of p300 through the EP domain might be involved in Notch-1-mediated gene regulation.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Plasmids.
The murine Notch-1-IC cDNA was isolated from
pSG5mNotch1IC (15) by digestion with KpnI and
XbaI and subcloned into the expression vector pcDNA3
(InVitrogen). The C-terminal deletion constructs mNotch-1-X/XB,
mNotch-1-P/XB, mNotch-1-E/XB, mNotch-1-N/XB, and mNotch-1-Eh/XB were
made by digestion of pcDNA3-mNotch-1-IC with XbaI and
XhoI (mNotch-1-X/XB), PvuII (mNotch-1-P/XB),
EcoRV (mNotch-1-E/XB), NotI (mNotch-1-N/XB), and
EheI (mNotch-1-Eh/XB) and religation of the blunted vectors.
The constructs mNotch-1-IC+OP, mNotch-1-TKG, and mNotch-1-SPN were made
by PCR. The 
RBP constructs correspond to the 1758WFP / LAA1760
mutation in the RAM domain of Notch-1 (47) and were made
by using an in vitro mutagenesis system (Stratagene), as
specified by the manufacturer's instructions, using the
double-stranded oligonucleotide
5'-GCATGGCCAGCTCTTGGCCGCGGAGGGTTTCAAAGTGTC-3'. The 
EP
in-frame deletions of mNotch-IC were constructed by
PvuII-EcoRV digestion and religation of the corresponding
mNotch-1 expression vectors. Further details of the construction of the
Notch-1 expression plasmids and the Notch-1-green fluorescent protein
(GFP) fusion constructs are available on request. The expression
vectors for E1A12S and for the N-terminal deletion mutant E1A12S
2-36
were described in references 30 and 52. The
p300-specific vectors for bacterial expression of glutathiona
S-transferase (GST) fusion proteins (p300 fragments N and A
to F) were made by PCR. The PCR products were inserted into the
BamHI and EcoRI sites of the bacterial expression
vector pGEX-2T (Pharmacia). The Notch-1-specific vector for bacterial
expression of GST-mNotch-1-IC, pGST-TKmNotch1IC, was described
previously (36). For generating the p300-expressing vector
pcDNA3-p300, the p300 cDNA was digested with HindIII and NotI. The DNA fragment was inserted into the corresponding
sites of pcDNA3. The C-terminally truncated p300 construct
pcDNA3-p300
C was generated by digestion of pcDNA3-p300 with
XbaI and religation of the vector. The expression vectors
pCMV-RBP-VP16 and pCMV-EBNA-2 were described in reference
48. The construction of pcDNA3-RBP-2N was described
previously (36).
N), originally constructed by David
Lane (University of Dundee), were supplied by Neil Perkins (University
of Dundee). The HES-1 promoter-specific reporter plasmid HES-1-LUC was
supplied by Urban Lendahl (Karolinska Institute, Stockholm, Sweden).
The luciferase reporter plasmid pGa981/6 was described previously
(29).
Cell lines. The cell lines HEK-293 (ATCC CRL 1573) and HeLa (ATCC CCL 2) were grown at 37°C under 5% CO2 in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% fetal calf serum.
Preparation of cell extracts. Whole-cell lysates were prepared as follows. Cells were washed three times in phosphate-buffered saline (PBS) and pelleted by centrifugation at 300 × g. The pellet was resuspended in 5 volumes of ice-cold CHAPS lysis buffer consisting of 10 mM 3-[(cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 50 mM Tris-HCl (pH 7.9), 150 mM NaCl, 2 mM EDTA, 5 mM NaF, 10 µg of aprotinin per ml, 10 µg of leupeptin per ml, 1 mM dithiothreitol (DTT), and 0.5 mM phenylmethylsulfonyl fluoride and incubated on ice for 40 min. The lysate was cleared by centrifugation at 80,000 × g for 30 min. Protein concentrations were determined by the Bradford method (Bio-Rad), and extracts were assayed for DNA binding activity in electrophoretic mobility shift assays (EMSA) and used for immunoprecipitation and Western blotting.
Translation of recombinant proteins. In vitro-translated proteins were synthesized in a reticulocyte lysate-coupled transcription-translation system as specified by the manufacturer (Promega), using [35S]methionine for labeling. The quality of translation and labeling was monitored by separation of the products using the sodium dodecyl sulfate (SDS)-gel electrophoresis method. The gels were dried and exposed to X-ray films. The labeled proteins were then used for in vitro interaction assays.
In vitro interaction assay. Purification of bacterially expressed GST fusion proteins and in vitro interaction assays were performed as described in reference 39.
EMSAs.
Approximately 5 to 10 µg of cell extract was used
for electromobility gel shift assays in a binding buffer consisting of
10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 0.1 mM EDTA, 0.5 mM DTT and 4%
glycerol. For binding reactions, 2 µg of poly(dl-dC) (Pharmacia) and
approximately 0.5 ng of 32P-labeled oligonucleotides
were added. The sequence of the double-stranded oligonucleotide, SL233
(5'-CCTGGAACTATTTTCCCACGGTGCCCTTCCGCCCATTTTCCCACGAGTCG-3'), corresponds to the two RBP-J
binding sites within the
Epstein-Barr virus TP-1 promoter. For antibody perturbation
experiments, 0.5 µg of antibody K0043, directed against RBP-J
(14), or 5 µg of antibody, directed against the FLAG
epitope (M5 [Sigma]), was added to the reaction mixture. The reaction
products were separated using 5% polyacrylamide gels with 1×
Tris-glycine-EDTA (TGE) at room temperature. The gels were dried and
exposed to X-ray films.
DNA transfection and luciferase assay. A total of 106 HEK-293 cells were transfected in 90-mm-diameter culture dishes with 5 to 10 µg of plasmid DNA expressing mammalian Notch-1 proteins using calcium phosphate coprecipitation, as described previously (40). At 24 h after transfection, nuclear proteins were prepared and the extracts were assayed for DNA binding activity, protein expression, and subcellular localization. HeLa cells were transfected essentially as described previously (35). Cells (2 × 105) in 35-mm-diameter culture dishes were transfected with 2 µg of reporter plasmid DNA together with various amounts of expression plasmid. To quantitate luciferase activity, cells were harvested 24 h after transfection and lysed for 10 min at room temperature in 120 µl of buffer containing 25 mM Tris-HCl (pH 7.8), 2 mM EDTA, 2 mM DTT, 10% glycerol, and 1% Triton X-100. The lysates were centrifuged at 7,000 × g for 5 min. Luciferase activity was determined from at least four independent transfections with 20 µl of cleared lysate in an LB 9501 luminometer (Berthold) using the luciferase assay system from Promega. All transfections were normalized on the level of total cellular protein.
Western blotting. SDS-polyacrylamide gels (10 or 7.5% polyacrylamide) were transferred at room temperature to a nitrocellulose filter (BA85; Schleicher & Schuell) for 20 min at 150 mA, using a Tris-glycine buffer system. The membrane was blocked for 2 to 3 h in a solution of 5% milk powder in PBS-T (0.05% Tween 20 in PBS), incubated with the primary antibody directed against the FLAG epitope (M5) for 1 to 2 h in PBS-T containing 5% milk powder, and then washed three times for 10 min in PBS-T. The secondary antibody (1:7,000 dilution of peroxidase-conjugated sheep anti-mouse immunoglobulin G [IgG] [Sigma]) was incubated with the membrane for 30 min. To analyze immunoprecipitated proteins, membranes were sectioned horizontally such that the two proteins of interest (p300 and Notch-1) remained on separate segments of the membrane. After blocking, the sections were incubated with the corresponding primary antibodies, anti-p300 (mouse monoclonal IgG [Upstate]) or anti-Notch-1 (M20, goat polyclonal IgG [Santa Cruz]) at 4°C overnight. The secondary antibodies (1:7,000) dilution of peroxidase-conjugated sheep anti-mouse IgG [Sigma] and 1:30,000 dilution of peroxidase-conjugated rabbit anti-goat IgG [Dianova]) were incubated with membrane sections for 1 h. After washing, specific proteins were detected using an enhanced chemiluminescence system (Amersham).
Coimmunoprecipitation.
Immunoprecipitation was carried out
with cell extracts from HEK-293 cells 24 h after transfection with
pcDNA3-mNotch-1-IC+OP and pcDNA3-mNotch-1-IC+OP-
EP. The cells were
lysed in 900 µl of CHAPS lysis buffer. Extracts were incubated with
40 µl of an agarose-conjugated anti-p300 antibody (N15AC [Santa
Cruz]) at 4°C overnight. The mixture was divided into three
aliquots, and the beads were washed three times with CHAPS lysis buffer
containing 150, 500, and 1,000 mM LiCl. After a further washing
step with CHAPS lysis buffer containing 150 mM LiCl, the beads were
resuspended in SDS-polyacrylamide gel loading buffer and proteins were
analyzed by Western blotting.
| |
RESULTS |
|---|
|
|
|---|
RBP-J
binding is critical for full Notch-1-IC mediated
transactivation.
To test Notch-1-specific transcriptional
activation by various Notch-1-IC mutant proteins, we used the
artificial RBP-J
-responsive reporter construct, pGa981/6. This
luciferase reporter plasmid carries six repeats of the
EBNA-2-responsive element within the Epstein-Barr Virus TP-1 promoter
upstream of a minimal
-globin promoter, resulting in a construct
with 12 RBP-J
binding sites (Fig. 1A).
Cotransfection of RBP-2N (9) into HeLa cells had no effect
on the transcriptional activity of the promoter construct (Fig.
2). In contrast, expression of RBP-VP16
resulted in a clear stimulation of promoter activity. As an additional
control, we used an EBNA-2 expression plasmid (48).
Overexpression resulted in approximately 50-fold stimulation.
Cotransfection of the intracellular domain of the murine Notch-1
protein (mNotch-1-IC [Fig. 1B]) resulted in a dramatic increase of
promoter activity (Fig. 2). This stimulation was nearly lost when we
used Notch-1 mutants where the primary RBP-J
binding site within the
RAM domain was mutated (mNotch-1-IC
RBP and mNotch-1-IC+OP
RBP
[Fig. 1B]). These experiments demonstrate, that the artificial
promoter construct pGa981/6 is a suitable tool for analyzing Notch
mediated transcriptional regulation.
|
|
Dominant negative effect of mNotch-1-IC
RBP in
mNotch-1 mediated transcription.
Recently, it was shown that
the intracellular domain of Notch-3 represses Notch-1-mediated
transcriptional activation (5). The authors presented a
model in which this repression may be due to competition with
Notch-1-IC for a common coactivator present in limiting amounts. If
this limiting cofactor exists, a Notch-1 mutant defective in RBP-J
binding should compete for this factor with the wild-type
Notch-1-IC protein. To address this question, we performed
cotransfection experiments using the reporter constructs described
above, Notch-1-IC and Notch-1-IC
RBP. Cotransfection of increasing
amounts of mNotch-1-IC together with pcDNA3 as a control resulted in a
clear stimulation of promoter activity. This transactivation was
significantly suppressed after coexpression of the Notch-1 mutant
mNotch-1-IC
RBP (Fig. 3). These results demonstrate that like Notch-3-IC, the mNotch-1-IC
RBP mutant
represses Notch-mediated transcription, possibly by cofactor
competition.
|
Transcriptional activity of mNotch-1 deletion constructs.
To
gain further insight in the transcriptional activity of intracellular
Notch-1 proteins, we used deletion constructs shown in Fig. 1B. The
results of cotransfection of the reporter plasmid pGa981/6 and
Notch-1-specific deletion mutants into HeLa cells are shown in Fig.
4. Stimulation of promoter activity of
about 200- to 250-fold was observed after cotransfection of
mNotch-1-IC, mNotch-1-X/XB (aa 1751 to 2183), and mNotch-1-TKG
(aa 1751 to 2154) into HeLa cells. Further C-terminal deletions in the
constructs mNotch-1-SPN (aa 1751 to 2132) and mNotch-1-P/XB (aa 1751 to
2113) led to a small decrease of transcriptional activity. However, we
still observed a 100-fold stimulation of promoter activity. Interestingly, after deletion of an additional 15 aa in mNotch-1-E/XB (aa 1751 to 2097), we could not detect any activation of the reporter construct in cotransfection experiments (Fig. 4). Loss of
transcriptional activity was also observed after cotransfection of
mNotch-1-N/XB (aa 1751 to 2025) and mNotch-1-Eh/XB (aa 1751 to 1907).
Note that all of the mNotch-1 deletion constructs used in this
experiment have an intact RAM domain and are capable of RBP-J
binding. In addition, in all deletion mutants except for mNotch-1-N/XB
and mNotch-1-Eh/XB, the ankyrin domain is not affected by deletion (Fig. 1B). Therefore, we assume that a distinct domain in mNotch-1 (aa
2098 to 2113) C-terminal to the ankyrin repeats is indispensable for
transactivation. We named this novel domain the EP domain.
|
Detection of RBP/Notch-1 complexes by EMSA.
To investigate the
formation of RBP complexes with selected Notch-1 deletion mutants, we
performed band shift experiments (Fig.
5). HEK-293 cells were transiently
transfected with plasmids expressing Notch-1-IC and deletion mutants.
Expression of the mutant Notch-1 proteins was verified by Western blot
analysis (data not shown). As a control, we used in vitro-translated
RBP-J
protein (Fig. 5, lanes 13 and 14). The RBP-J
-specific
complex (band A, lane 13) was supershifted after addition of an
antibody (K0043), directed against RBP (band B, lane 14). As expected, an RBP-J
specific complex (complex A) could already be identified in
extracts of untransfected HEK-293 cells (lanes 1 and 2). Addition of an
antibody directed against the FLAG epitope did not interfere with
RBP-J
DNA binding (lane 2). The endogenous RBP-J
-specific DNA
binding activity was markedly decreased in extracts from HEK-293 cells
transfected with 5 µg of a plasmid expressing mNotch-1-IC. In these
extracts, a novel, slower-migrating complex (band C) appeared (lane 3).
Incubation of cell extracts with an antibody directed against the FLAG
epitope supershifted complex C, resulting in complex D, which most
probably contains Notch-1-IC interacting with RBP-J
(lane 4).
Similar results were obtained with extracts from cells
transfected with mNotch-1-X/XB (lanes 5 and 6) and mNotch-1-P/XB (lanes
7 and 8). Interestingly, in extracts from mNotch-1-P/XB-transfected
cells, a novel complex could be detected (band E) in addition to the
higher-order complex C (lane 7). This band also interferes with the
anti-FLAG antibody, suggesting that this complex contains Notch-1
protein (lane 8). The novel complex could also be detected in extracts
from cells transfected with mNotch-1-E/XB (lanes 9 and 10) and
mNotch-1-Eh/XB (lanes 11 and 12), but no higher-order complex (band C)
was generated. Note that all complexes E interfered with the anti-FLAG
antibody (lanes 8, 10, and 12). The different migration properties of
complexes E most probably result from different sizes of the mNotch-1
deletion mutants. Taken together, using band shift experiments, we
could detect two types of Notch-1/RBP complexes: (i) a slow migration complex (C) in extracts from HEK-293 cells transfected with
transcriptionally active Notch-1 proteins, and (ii) a novel complex
(E) in extracts from cells transfected with transcriptionally inactive
Notch-1 proteins. Only in extracts from mNotch-1-P/XB
transfected cells could we detect both complexes. As shown in Fig. 4,
this deletion mutant is still transactivating, although with lower
activity.
|
Transcriptional activity and subcellular localization of
Notch-1-IC-GFP proteins.
Three putative nuclear localization
signals have been identified within the mammalian Notch-1 protein
(3). To rule out any interference with the
subcellular localization of the mNotch-1 deletion proteins, we
used mNotch-1 mutants fused to GFP (Fig. 6A) in transfection and
cotransfection experiments. Protein expression (Fig. 6B) and
transcriptional activity (Fig. 6C) were assayed 24 h after
transfection. Western blot analysis revealed no significant variations
in the expression of the mNotch-1-GFP proteins (Fig. 6B).
Cotransfection of increasing amounts of mNotch-1-IC-GFP together with the RBP-J
reporter plasmid into HeLa cells resulted in a clear
stimulation of promoter activity. Cotransfection of increasing amounts
of mNotch-1-P/XB-GFP resulted in distinct but reduced stimulation
of promoter activity compared to that in mNotch-1-IC-GFP (Fig.
6C). In contrast, we could not detect any significant increase of
transcriptional activity after cotransfection of
mNotch-1-IC
RBP-GFP, mNotch-1-E/XB-GFP, or
mNotch-1-Eh/XB-GFP.
|
RBP-GFP (panel c),
mNotch-1-P/XB-GFP (panel d), and mNotch-1-E/XB-GFP (panel e),
although the last two lack the nuclear localization signals 2 and 3. Only the shortest mNotch-1-GFP protein mNotch-1-Eh/XB-GFP,
which lacks most of the ankyrin repeats (Fig. 6A), revealed a different
localization pattern in transfected HEK-293 cells: most of the protein
is found in the nucleus, but the speckled pattern is lost (panel f).
Therefore, loss of transcriptional activity after deletion of the EP
domain does not correlate with a change in subcellular localization of
the mNotch-1 proteins. Transcriptionally, inactive mNotch-1
mutants still translocated into the nucleus.
Repression of Notch-1-mediated transactivation by E1A12S and
p53.
It was shown previously that the adenovirus E1A12S protein
interferes with coactivator function (8, 12, 49). To
investigate whether E1A interferes with Notch-1-mediated
transcription, we performed cotransfection experiments using the
RBP-J
reporter plasmid and expression plasmids for E1A12S and
Notch-1 proteins. Luciferase activity of pGa981/6 was stimulated
240-fold following cotransfection of pcDNA3-mNotch-1-IC+OP. This
stimulation was abrogated to basal levels by gradually increasing the
amounts of E1A12S. Repression of Notch-1-mediated transcriptional
activation was not observed when the N-terminal deletion mutant
E1A12S
2-36 was used (Fig. 7A). Similar
results were obtained when the C-terminal deletion mutant
mNotch-1-IC, missing the OPA and PEST sequences, was used.
Cotransfection resulted in 160-fold stimulation of promoter activity,
which again was reduced to basal levels by gradually increasing the
amount of an E1A12S expression plasmid (Fig. 7B). The inhibitory effect
of E1A12S on Notch-1-mediated transcription indicated that
coactivators of the p300 family might be involved in this process. For
this reason, we used a second protein, p53, which was shown to be an
inhibitory indicator of p300-dependent transactivation
(50). The experiments were performed with murine p53 (p53
mm-wt) and human p53 (p53 hs-wt), which both strongly repressed
Notch-1-mediated transcription (Fig. 7C). Deletion of the
N-terminal 43 aa, which are important for p300 interaction in
p53mm
N, abolished the repressive effect of p53. These results demonstrate that E1A12S and p53 are able to suppress
Notch-1-mediated transcription. This repression depends on the
N-terminal sequences of E1A12S and p53.
|
Notch-1-IC interacts with the CH3 region of p300.
Physical
interactions between mNotch-1-IC and the transcriptional
coactivator p300 were analyzed in vitro by pull-down assays with GST
fusion proteins. The p300-derived fragments N, A, B, C, D, E, and F
shown in Fig. 8A were fused to GST and
expressed in Escherichia coli. Glutathione-Sepharose beads
were coated with recombinant GST or the GST fusion proteins and used as
bait for cell-free synthesized and radiolabeled Notch-1-IC protein
(Fig. 8C) or radiolabeled p300 protein (Fig. 8D). Radiolabeled E1A
(Fig. 8B) was used as a control. As shown previously (52),
strong interaction of E1A with p300 fragments B and D was observed
whereas fragments A and C and the amino terminus of p300 revealed only a weak interaction with E1A. No interaction could be detected with
fragments E and F and with GST protein alone (Fig. 8B). In contrast,
interaction of Notch-1-IC and p300 could be detected exclusively
with fragment B (Fig. 8C). This Notch-1-IC interaction domain
partially overlaps the CH3 region of p300 (Fig. 8A). Interaction of
Notch-1-IC with p300 was also observed when GST mNotch-1-IC was
used as bait for cell-free-synthesized p300 (Fig. 8D). The interaction
of p300 with GST-mNotch-IC depends on the C-terminal part of p300,
since cell-free-synthesized p300
C (aa 1 to 1302) failed to interact
with the bait (Fig. 8D).
|
Notch-1-IC/p300 interaction correlates with transcriptional
activity.
Next we asked which part of Notch-1-IC is
responsible for p300 interaction. To do this we performed a set of
pull-down experiments with p300 fragment B fused to GST and various
C-terminal deletion mutants of Notch-1-IC. As shown in Fig.
9, the C-terminal deletion mutants
mNotch-1-X/XB and mNotch-1-TKG still interact with fragment B
of p300. Further deletion in mNotch-1-SPN and mNotch-1-P/XB led
to some loss of interaction capacity with fragment B. The interaction
was further reduced using mNotch-1-E/XB, mNotch-1-N/XB, and
mNotch-1-Eh/XB (Fig. 9A). A densitometric analysis of the results
of six pull-down experiments is shown in Fig. 9B. Taken together, the
results of these mapping experiments show that Notch-1-IC proteins
are capable of interacting with p300 as long as they contain at least
residues 2097 to 2113, the EP domain. Interestingly, interaction of the
mNotch-1-IC-derived deletion mutants with GST-p300 fragment B
correlates with their transcriptional potential in our cotransfection
experiments (Fig. 4 and 6C).
|
Notch-1-p300 interaction in vivo.
Coimmunoprecipitation
experiments were performed to prove the existence of a physical
interaction of p300 with mNotch-1-IC in vivo. Since it is not
feasible to detect endogenous activated Notch in the nucleus by
immunological methods (41), we decided to perform these
experiments with transfected Notch-1 constructs. HEK-293 cells were
transiently transfected with plasmids expressing mNotch-1-IC+OP or
mNotch-1-IC+OP
EP. Expression of Notch-1 proteins, as well as
endogenous p300 protein, was verified by Western blotting (Fig.
10, lanes 1 and 2). The quality of the
p300 immunoprecipitation was monitored in untransfected HEK-293 cells.
The amount of p300 protein in cell lysates (lane 3) decreased after
incubation with the anti-p300 antibody (lane 4) and accumulated in the
precipitate (lane 6). When the anti-p300 antibody was used for
immunoprecipitation, Notch-1 protein was coimmunoprecipitated
(lane 7), whereas no Notch-1 protein was found when agarose beads
alone were used (lane 5). This interaction was specific, since addition
of a blocking peptide (p300-N15P [Santa Cruz]) directed against the
p300 antibody abolished the coimmunoprecipitation (lanes 8 and 9).
Interaction of mNotch-1-IC+OP with endogenous p300 appears to be
very stable, since extensive washing with 500 mM LiCl (lane 11) and
1,000 mM LiCl (lane 12) did not interfere with binding. In
contrast, interaction of p300 with mNotch-1-IC+OP-
EP (lane 13)
decreased after washing with 500 mM LiCl (lane 14) and 1,000 mM
LiCl (lane 15). These results indicate that (i) Notch-1-IC binds to
endogenous p300 in vivo, (ii) this interaction seems to be rather
stable, and (iii) deletion of the EP domain in Notch-1-IC
destabilizes this interaction.
|
Mutational analysis of the EP domain within mNotch-1-IC.
To identify amino acids within the EP domain critical for
mNotch-1-mediated transactivation, we used
mNotch-1-IC-specific scanning mutants (Fig.
11A). Expression of the
mNotch-1-IC mutants was verified by Western analysis after
transient transfection of the corresponding expression plasmids into
HEK-293 cells (Fig. 11C). Cotransfection of plasmids expressing
wild-type mNotch-1-IC together with the reporter plasmid pGa981/6
into HeLa cells resulted in 200-fold stimulation of luciferase
activity. Interestingly, only one scanning mutation within the EP
domain, mNotch-1-IC-2102 LDE/AAA 2104 resulted in complete loss of
transcriptional activity, which was comparable to that of
mNotch-1-IC
EP. Cotransfection of the remaining mNotch-1-IC
scanning mutants resulted in no or only a weak decrease in
transactivation potential (Fig. 11B). These results demonstrate that
within the EP domain of mNotch-1-IC, at least 3 aa (2102 LDE 2104)
are critical for transactivation. In addition, this LDE motif within
the EP domain is highly conserved in Notch proteins of various species
(Fig. 11D).
|
Additive effect of p300 in Notch-1-mediated
transactivation.
To test the cooperation of Notch-1-IC and
p300 on a functional level, we performed cotransfection experiments
with HeLa cells using the RBP-J
reporter and expression plasmids for
p300 and the intracellular domain of mNotch-1 (Fig.
12). Stimulation of luciferase activity
from the reporter construct by Notch-1-IC expression was further
enhanced after gradually increasing the amounts of p300. Similar
results were obtained when an expression plasmid for Notch-1-IC+OP
was used (data not shown). In contrast, we could not detect any
increase of luciferase activity when we used the
Notch-1-IC-specific scanning mutant LDE/AAA in this assay (Fig.
12). These results demonstrate that the additive effect of p300 in
Notch-1-mediated transactivation is dependent on a functional EP
domain.
|
Transcriptional activation of the murine HES-1 promoter by
Notch-1-IC depends on the EP domain.
HES-1 was identified as a
Notch target gene in mammals (17, 18, 25). To test the
effect of the EP domain in Notch-1-IC-mediated transcription on a
naturally existing promoter, we performed cotransfection experiments with the human HES-1 promoter fused to the luciferase gene. Cotransfection of either mNotch-1-IC or
mNotch-1-IC+OP led to a clear stimulation of HES-1 promoter
activity (Fig. 13). Deletion of the EP
domain in mNotch-1-IC
EP resulted in nearly complete loss of
transcriptional activity, whereas the Notch-1 mutant
mNotch-1-IC+OP
EP was still able to activate transcription from
the HES-1 promoter to some extent. This might be due to a
transactivation domain, which was mapped to the C-terminal OPA and PEST
sequences of mNotch-1 (10, 27). These results
demonstrate that the identified EP domain is a prerequisite for full
transcriptional activity of the intracellular domain of mNotch-1.
|
| |
DISCUSSION |
|---|
|
|
|---|
One mechanism by which Notch-1-IC exerts its function is the
conversion of the DNA binding protein RBP-J
/CBF-1 from a repressor to an activator of transcription. Three domains of Notch-1-IC are
important for transactivation including, RAM, ankyrin repeats, and TAD.
The RAM domain represents the primary binding site to RBP-J
and was
shown to be important for transactivation activity of Notch-1-IC
through displacement of a putative corepressor from RBP-J
(15,
20, 47). Within this interaction domain, a stretch of 3 aa, WFP
(aa 1758 to 1760), is critical for the interaction of Notch-1-IC
with RBP-J
(47). We found that a mutant form of
Notch-1-IC, mNotch-1-IC
RBP, with a substitution of WFP to LAA, slightly transactivates a reporter gene containing multiple RBP-J
binding sites (Fig. 2). This is in agreement with earlier data
showing that Notch-1-IC lacking the RAM domain can still activate
transcription of the HES genes but does so less strongly than
Notch-1-IC does (17, 21). In addition,
mNotch-1-IC
RBP, when cotransfected with Notch-1-IC,
repressed the transactivation of a reporter construct in
trans, suggesting coactivator competition (Fig. 3).
Similarly, Notch-3-IC represses Notch-1-IC-mediated transcriptional
activation (5). This inhibition has been suggested to
rely on competition of common coactivators, which are known to be
present in limiting amounts. To identify domains important for
transcriptional activation of Notch-1-IC, C-terminal deletion constructs were tested for their ability to transactivate a reporter plasmid. The results show that a region C-terminal of the ankyrin repeats is important for transactivation. A construct,
mNotch-1-E/XB, lacking this region did not exhibit any activity
(Fig. 4). We called this putative transactivation domain the EP domain.
Interestingly, this region is highly conserved among Notch proteins of
various species (Fig. 11D).
An autonomous transactivation domain, TAD, has been identified in mouse Notch-1 (10, 22, 27). This domain was mapped to 200 aa containing the OPA sequence, although the OPA sequence alone was unable to mediate the transactivation function. We also found a sequential loss of transcriptional activity using the C-terminal deletion, but most of the transcriptional activity of Notch-1-IC remains after deleting TAD and is completely abolished only after C-terminal deletion of the EP-domain.
The EP domain in Notch-1 is also important for transactivation of a
promoter construct derived from a well-characterized Notch target gene,
HES-1. The Notch-1-specific deletion mutant mNotch-1-IC
EP completely lost its ability to activate the HES-1 promoter (Fig. 13).
Interestingly, the addition of the C-terminal OPA sequences, mNotch-1-IC+OP
EP, rescued some of its transcriptional activity, suggesting that the function of TAD depends only in part on an intact
EP domain.
In addition to impaired transcriptional function, we find a loss of
protein-DNA interaction by Notch mutants lacking the EP domain. The
interaction of Notch-1-IC with RBP-J
bound to an appropriate
oligonucleotide probe can be visualized by EMSA as a slowly migrating
higher-order complex (17, 36). Mutants of Notch-1-IC
with C-terminal deletions in the previously described TAD still
give rise to a higher-order complex containing Notch-1-IC/RBP. In
contrast, this complex failed to form with transcriptional inactive
mutants (Fig. 5). These data suggest the presence of a putative
cofactor(s) forming a higher-order complex with transcriptionally active Notch-1 mutants.
In addition to TAD and the novel EP domain, ankyrin repeats are be
important for transactivation. Missense mutations in the ankyrin
repeats of mouse Notch-1 show loss-of-function phenotypes (21, 23). An autonomous function for the ankyrin domain
independent of RBP-J
signaling has been described in
Caenorhabditis elegans and in mouse muscle cell
differentiation (31, 38, 42). Recently, the ankyrin
repeats were identified as target sequences for MAML-1 interaction. In
this report, MAML-1, the human homologue of Drosophila Mastermind, acts as a transcriptional coactivator for Notch
proteins (51). The question remains how these domains,
ankyrin repeats, EP domain, and TAD, act together to confer strong transactivation.
The transactivation function of Notch-1-IC can be antagonized by
the adenovirus protein E1A12S. This repression was not observed when
the deletion mutant E1A12S
2-36 was used. Several studies have shown
that E1A12S blocks p300/CBP coactivator functions (8, 12,
45). This does not exclude the involvement of other coactivators in Notch-1-mediated transactivation, since E1A12S was also shown to
interfere with P/CAF function (26). Similar to E1A12S, p53 can repress Notch-1-IC-mediated transcription, whereas the deletion mutant p53
N, which cannot interact with p300, does not have any repressive effect (50). Therefore, it is likely that
E1A12S and p53 function in part by preventing Notch-1-IC from
association with p300.
The results we obtained using several approaches support the hypothesis that the common coactivator p300 might be involved in Notch-1-dependent gene expression. (i) Notch-1-IC-mediated transcriptional activation was inhibited by E1A12S and p53, two proteins which interfere with p300 functions (Fig. 7). (ii) Notch-1-IC interacts with the CH3 region of p300 (Fig. 8). (iii) p300 interacts with a distinct domain of Notch-1-IC essential for full transcriptional activation (Fig. 9). (iv) Notch-1-IC/p300 interaction correlates with transcriptional activity. (v) Notch1-IC forms a stable complex with p300 in vivo (Fig. 10). (vi) Notch-1-IC and p300 display some additive effects on transactivation, and these effects depend on a functional EP domain (Fig. 12).
Ordentlich et al. demonstrated Notch-1-IC- and Notch-2-IC-mediated repression of E47 activity (34). MyoD responds to Notch in a similar fashion (23). Although MyoD and E47 both utilize p300 as cofactors, the authors could not confirm a role for p300 in that context. The conclusion was based on the inability of Notch-1-IC to alter GAL4-p300-mediated gene expression. Moreover, GAL4-E47, E47-VP16, GAL4-MyoD, and MyoD-VP16 are all resistant to inhibition by Notch (23). This would not necessarily be contradictory to our results but points to the requirement for additional structural features.
Coactivators like p300 contribute to transcriptional regulation by modifying chromatin structure via association with members of the p160/SRC family of coactivators, as well as with P/CAF. While our work was in progress, Kurooka and Honjo reported that mouse P/CAF and GCN5 interact with Notch1-IC (26). P/CAF and GCN5 require the ankyrin repeats in addition to the previously characterized domain, TAD. The aa 2098-to-2193 sequence within Notch-1, which is involved in p300 binding is not required for interaction with P/CAF or GCN5. Therefore, two possibilities could be discussed: (i) either p300 binds primarily to Notch-1 and recruits molecules with additional HAT activity, like P/CAF, or (ii) P/CAF and GCN5 bind first and build the starting point for the formation of a larger complex. A synergism between multiple coactivator proteins has been described for the transactivation functions of hepatocyte nuclear factor 1 (HNF-1). The authors support a model in which the combined action of coactivators (here CBP and P/CAF) is recruited by HNF-1 to activate transcription (43). The interaction of a multiprotein complex including P/CAF and GCN5 with the intracellular domain of Notch-1 is an attractive model, which remains to be established.
Recently, domains of Notch-1 which are important for transformation
of E1A-immortalized baby rat kidney cells in vitro have been
characterized (6). These mapped sequences overlap with the
EP domain. Neoplastic transformation by Notch is likely to be RBP-J
independent, although this process requires nuclear translocation of
Notch (10, 19). One possible explanation for the role of
the EP domain in this transformation process might be a transcriptional
cross talk between Notch-1 and the tumor suppressor protein p53.
Notch-1 and other p300-associated transcription factors compete for
limiting quantities of complexes containing p300 and other coactivator
proteins. Notch might block p300 function, and the effect on cell
transformation might occur by inhibiting the actions of p53. In this
model, Notch-1 could be viewed as having an effect of promoting
resistance to apoptosis. A similar regulation between RelAp65 and p53
has been previously suggested (50).
On a functional level, a 3-aa substitution within the EP domain (2102 LDE/AAA 2104) leads to a clear reduction of Notch-1-mediated transactivation, which was comparable to that of the
EP mutant. In
addition, the additive effect of p300 in Notch-mediated transactivation is completely lost by the LDE mutant protein (Fig. 12). On the other
hand, the in vivo interaction of the Notch-1-
EP mutant with p300
is not completely abolished but appears to be sensitive to high salt
concentrations. Therefore, we found some discrepancies between our
functional and biochemical data. From our pull-down experiments, one
could speculate that in addition to the EP domain, C-terminal sequences
might be necessary for full p300 binding to Notch-1 in vivo.
However, a deletion construct lacking these C-terminal sequences
(mNotch-1-P/XB) is still transcriptionally active. Only a further
deletion of an additional 15 aa (mNotch-1-E/XB) leads to a
transcriptionally inactive Notch-1 protein, and this mutant fails
to interact with p300 in our GST pull-down assays. Taken together,
these results raise the question whether the function of p300 as
a coactivator for Notch-1-mediated transcription depends mainly on
the strength of interaction or whether the situation is more
complex. In this context, it is important to note that very recently, a
novel, more dynamic role for DNA binding proteins was considered when
another transcription factor, HNF-1
, was studied. Two naturally
existing mutant forms of this transcription factor are still able to
recruit coactivators; however, the interaction is nonproductive
(44). The authors support a model in which transcription
factors not only recruit coactivators but also modulate their enzymatic
activity. This idea might explain the fact that a transcriptionally
inactive Notch-1 mutant protein still interacts with p300 to some extent.
In this study, we have identified and characterized a novel domain in Notch-1-IC, the EP domain, which is important for a Notch-1-IC/p300 interaction. The interaction of this common coactivator with Notch-1 adds another level of complexity to this signaling pathway. Other p300 binding proteins may directly influence Notch-mediated transactivation and thus explain at least in part the pleiotropic involvement of Notch in the complex biological processes that affect cell growth, transformation, and differentiation.
| |
ACKNOWLEDGMENTS |
|---|
We thank U. Wegenka, G. Schneider, U. Zechner, and H. Häcker for critically reading the manuscript. We also thank T. Honjo for providing the RBPJ
-specific antibody, K0043, and N. Perkins for providing the p53-expressing plasmids. For excellent
technical assistance we thank J. Koehler, R. Rittelmann, and C. Heber.
This study was supported by the Deutsche Forschungsgemeinschaft, Sonderforschungsbereich 322,C4, to S.L. and R.M.S.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Internal Medicine I, Robert-Koch-Strasse 8, D-89081 Ulm, Germany. Phone: 49-731-50-24305. Fax: 49-731-50-24302. E-mail: roland.schmid{at}medizin.uni-ulm.de.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Arias, J., A. S. Alberts, P. Brindle, F. X. Claret, T. Smeal, M. Karin, J. Feramisco, and M. Montminy. 1994. Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. Nature 370:226-229[CrossRef][Medline]. |
| 2. |
Artavanis-Tsakonas, S.,
M. D. Rand, and R. J. Lake.
1999.
Notch signaling: cell fate control and signal integration in development.
Science
284:770-776 |
| 3. |
Aster, J. C.,
E. S. Robertson,
R. P. Hasserjian,
J. R. Turner,
E Kieff, and J. Sklar.
1997.
Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-J or nuclear localization sequences retain the ability to associate with RBP-J and activate transcription.
J. Biol. Chem.
272:11336-11343 |
| 4. |
Bailey, A. M., and J. W. Posakony.
1995.
Suppressor of hairless directly activates transcription of enhancer of split complex genes in response to Notch receptor activity.
Genes Dev.
9:2609-2622 |
| 5. | Beatus, P., J. Lundkvist, C. Oberg, and U. Lendahl. 1999. The notch 3 intracellular domain represses notch 1-mediated activation through Hairy/Enhancer of split (HES) promoters. Development 126:3925-3935[Abstract]. |
| 6. | Capobianco, A. J., P. Zagouras, C. M. Blaumueller, S. Artavanis-Tsakonas, and J. M. Bishop. 1997. Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. Mol. Cell. Biol. 17:6265-6273[Abstract]. |
| 7. | Chakravarti, D., V. J. LaMorte, M. C. Nelson, T. Nakajima, I. G. Schulman, H. Juguilon, M. Montminy, and R. M. Evans. 1996. Role of CBP/P300 in nuclear receptor signalling. Nature 383:99-103[CrossRef][Medline]. |
| 8. | Chakravarti, D., V. Ogryzko, H. Y. Kao, A. Nash, H. Chen, Y. Nakatani, and R. M. Evans. 1999. A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell 96:393-403[CrossRef][Medline]. |
| 9. |
Dou, S.,
X. Zeng,
P. Cortes,
H. Erdjument-Bromage,
P. Tempst,
T. Honjo, and L. D. Vales.
1994.
The recombination signal sequence-binding protein RBP-2N functions as a transcriptional repressor.
Mol. Cell. Biol.
14:3310-3319 |
| 10. | Dumont, E., K. P. Fuchs, G. Bommer, B. Christoph, E. Kremmer, and B. Kempkes. 2000. Neoplastic transformation by Notch is independent of transcriptional activation by RBP-J signalling. Oncogene 19:556-561[CrossRef][Medline]. |
| 11. | Egan, S. E., B. St. Pierre, and C. C. Leow. 1998. Notch receptors, partners and regulators: from conserved domains to powerful functions. Curr. Top. Microbiol. Immunol. 228:273-324[Medline]. |
| 12. |
Feng, X. H.,
Y. Zhang,
R. Y. Wu, and R. Derynck.
1998.
The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF- -induced transcriptional activation.
Genes Dev.
12:2153-2163 |
| 13. | Fortini, M. E., and S. Artavanis-Tsakonas. 1994. The suppressor of hairless protein participates in Notch receptor signaling. Cell 79:273-282[CrossRef][Medline]. |
| 14. |
Hamaguchi, Y.,
Y. Yamamoto,
H. Iwanari,
S. Maruyama,
T. Furukawa,
N. Matsunami, and T. Honjo.
1992.
Biochemical and immunological characterization of the DNA binding protein. (RBP-J ) to mouse J recombination signal sequence.
J. Biochem. (Tokyo)
112:314-320 |
| 15. |
Hsieh, J. J.,
T. Henkel,
P. Salmon,
E. Robey,
M. G. Peterson, and S. D. Hayward.
1996.
Truncated mammalian Notch1 activates CBF1/RBPJ -repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2.
Mol. Cell. Biol.
16:952-959[Abstract].
|
| 16. |
Hsieh, J. J.,
S. Zhou,
L. Chen,
D. B. Young, and S. D. Hayward.
1999.
CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex.
Proc. Natl. Acad. Sci. USA.
96:23-28 |
| 17. | Jarriault, S., C. Brou, F. Logeat, E. H. Schroeter, R. Kopan, and A. Israel. 1995. Signalling downstream of activated mammalian Notch. Nature 377:355-358[CrossRef][Medline]. |
| 18. |
Jarriault, S.,
B. O. Le,
E. Hirsinger,
O. Pourquie,
F. Logeat,
C. F. Strong,
C. Brou,
N. G. Seidah, and A. Israel.
1998.
Delta-1 activation of notch-1 signaling results in HES-1 transactivation.
Mol. Cell. Biol.
18:7423-7431 |
| 19. |
Jeffries, S., and A. J. Capobianco.
2000.
Neoplastic transformation by Notch requires nuclear localization.
Mol. Cell. Biol.
20:3928-3941 |
| 20. |
Kao, H. Y.,
P. Ordentlich,
N. Koyano,
Z. Tang,
M. Downes,
C. R. Kintner,
R. M. Evans, and T. Kadesch.
1998.
A histone deacetylase corepressor complex regulates the Notch signal transduction pathway.
Genes Dev.
12:2269-2277 |
| 21. | Kato, H., Y. Taniguchi, H. Kurooka, S. Minoguchi, T. Sakai, S. Nomura-Okazaki, K. Tamura, and T. Honjo. 1997. Involvement of RBP-J in biological functions of mouse Notch1 and its derivatives. Development 124:4133-4141[Abstract]. |
| 22. |
Kidd, S.,
T. Lieber, and M. W. Young.
1998.
Ligand-induced cleavage and regulation of nuclear entry of Notch in Drosophila melanogaster embryos.
Genes Dev.
12:3728-3740 |
| 23. |
Kopan, R.,
J. S. Nye, and H. Weintraub.
1994.
The intracellular domain of mouse Notch: a constitutively activated repressor of myogenesis directed at the basic helix-loop-helix region of MyoD.
Development
120:2385-2396 |
| 24. | Kornberg, R. D., and Y. Lorch. 1999. Chromatin-modifying and -remodeling complexes. Curr. Opin. Genet. Dev. 9:148-151[CrossRef][Medline]. |
| 25. |
Kuroda, K.,
S. Tani,
K. Tamura,
S. Minoguchi,
H. Kurooka, and T. Honjo.
1999.
Delta-induced Notch signaling mediated by RBP-J inhibits MyoD expression and myogenesis.
J. Biol. Chem.
274:7238-7244 |
| 26. |
Kurooka, H., and T. Honjo.
2000.
Functional interaction between the mouse notch1 intracellular region and histone acetyltransferases PCAF and GCN5.
J. Biol. Chem.
275:17211-17220 |
| 27. |
Kurooka, H.,
K. Kuroda, and T. Honjo.
1998.
Roles of the ankyrin repeats and C-terminal region of the mouse notch1 intracellular region.
Nucleic Acids Res.
26:5448-5455 |
| 28. |
Lecourtois, M., and F. Schweisguth.
1995.
The neurogenic suppressor of hairless DNA-binding protein mediates the transcriptional activation of the enhancer of split complex genes triggered by Notch signaling.
Genes Dev.
9:2598-2608 |
| 29. |
Minoguchi, S.,
Y. Taniguchi,
H. Kato,
T. Okazaki,
L. J. Strobl,
U. ZimberStrobl,
G. W. Bornkamm, and T. Honjo.
1997.
RBP-L, a transcription factor related to RBP-J .
Mol. Cell. Biol.
17:2679-2687[Abstract].
|
| 30. |
Nevels, M.,
B. Täuber,
E. Kremmer,
T. Spruss,
H. Wolf, and T. Dobner.
1999.
Transforming potential of the adenovirus type 5 E4orf3 protein.
J. Virol.
73:1591-1600 |
| 31. | Nofziger, D., A. Miyamoto, K. M. Lyons, and G. Weinmaster. 1999. Notch signaling imposes two distinct blocks in the differentiation of C2C12 myoblasts. Development 126:1689-1702[Abstract]. |